Bharat Edition

Bharatstox

← All stocks

Uflex Ltd.

NSE: UFLEX · Containers & Packaging

Sector

Containers & Packaging

Size band

Small cap

Market cap

2,495cr

P/E

16.3

ROE

6.8%

Dividend yield

0.9%

No price is shown on this page, live or delayed. It records what management said on the earnings call, and the company’s filings.

Measured against

Operating margin17.0%
peer 10.5%
Revenue growth37.6%
peer 19.3%
Uflex Ltd.peer median

Peer set

Containers & Packaging · 8 measured at Q1 FY27 · financials via Screener
CompanyOperating marginRevenue growth
Jindal Poly Films Ltd.1.4%−23.9%
Texmaco Rail & Engineering Ltd.8.0%−16.9%
AGI Greenpac Ltd.22.0%14.1%
Uflex Ltd.17.0%37.6%
TCPL Packaging Ltd.17.0%16.0%
Cosmo First Ltd.12.0%45.8%
Huhtamaki India Ltd.10.0%22.5%
Ester Industries Ltd.11.0%27.8%
Pyramid Technoplast Ltd.9.0%35.4%

What management said

16 statements on record

Earnings call · Q1 FY27 · 21 Aug 2026

  • Revenue growth→35% growth in our top line· FY27
    “I think we're expecting 35% growth in our top line in this financial year.”
  • EBITDA growth→same growth· FY27 compared to last financial year
    “And similarly, EBITDA also, we'll see the same growth coming up in this financial year as compared to last financial year.”
  • Top line and bottom line growth→30% plus· coming year
    “Both for top line and bottom line, you can expect a decent growth, 30% plus in coming year.”
  • Top line and bottom line growth→same growth· FY28
    “And same growth will continue in FY28 also because these capex’s, what are coming on a stream, this year where 2 have come on stream, 1 is coming up in the first half.”
  • Egypt Aseptic project commissioning→commissioning in FY27· FY27
    “Work on our Greenfield Aseptic project in Egypt, 12 billion packs remain on schedule for commissioning in FY27.”
  • Egypt Aseptic plant commissioning→H1· H1
    “See, right now, we do only greenfield projects and our project in Egypt Aseptic plant is up for commissioning, which will be done in H1, like we have said.”
  • Egypt Aseptic utilization→around 30% capacity· first year
    “We can see around 30% capacity being utilized there.”
  • Egypt Aseptic utilization→around 60% to 70%· Second year
    “Second year, certainly, we'll reach around 60% to 70%.”
  • Egypt Aseptic utilization→around 100% capacity· third year
    “And third year, we'll reach around 100% capacity there, so you can see how the buildup will happen, but Egypt being our second largest manufacturing site from UFlex global perspective, we are very well, I think, there to launch it very soon now, and you see the results coming up in Q3 and Q4 also.”
  • Egypt Aseptic volumes→around 2 billion· this financial year
    “In 6 months, the facility becomes 6 billion. And out of 6 billion, you say if we use capacity utilization is 30%, that's why I said 2 billion around that will be what will be used up in this financial year.”
  • Remaining Egypt capex→USD 15 million· going forward
    “First is Egypt one, which is coming up with a capacity of 12 billion packs, where we have already done a capex of over USD 100 million. And now only capex, what is remaining is USD 15 million, so not much capex is planned for Egypt now going forward.”
  • Dharwad capex→around USD 50+ odd million· FY27 and '28 put together
    “Similarly, Dharwad India, which is a Brownfield BOPP Line, where we have done a capex of USD 10 million. There we plan a good capex of around USD 50+ odd million, which we are planning for FY27 and '28 put together.”
  • Remaining capex→around USD 100 million or less USD 80 million capex· going forward
    “And whatever capex’s are remaining, which are new capex’s of around, if you put total all this will be around USD 100 million or less USD 80 million capex, we'll be doing going forward.”
  • Leverage→below 3x· by FY28
    “And this leverage will come down by end of FY28 much lower once all these capacities, what are not utilized to the 100% becomes 100% capacity utilization, then you will see our leverage going even below 3x by FY28, so we are very much conscious, aware of this fact that leverage has to be under control, which is under control because we are paying all loans on time, all interest on time, so that is least of a worry.”
  • Volume→double our quantity· next 3 years' time / FY29
    “See, if you add up the capacities what are coming up, if I can add up, we should double our quantity in next 3 years' time.”
  • Interest cost→reduce our interest costs by 1%· next 1 years' time
    “And whatever interest rate we are paying as of now and whatever rating we are enjoying, I am hopeful that we should reduce our interest costs by 1% in next 1 years' time.”

Taken from management commentary on the company’s earnings call and quoted verbatim. These are statements of intent made by the company, not forecasts by Bharatstox, and nothing here records whether they were met.

On air

5 calls · outcomes not tracked

Recorded as stated on air, with the analyst's SEBI registration status where it was given. Anchor calls carry no registration and are marked. Bharatstox does not make, endorse or repeat these calls, and none of them is our view.

Channel & showAiredStated targetStated stopOutcome
Zee BusinessZee Business · no registration attached2 Sep+12.4%-9.1%still open
Zee BusinessZee Business · no registration attached2 Sep+7.9%-9.1%still open
CNBC AwaazCNBC Awaax · no registration attached2 Sep+24.0%-13.2%still open
CNBC AwaazCNBC Awaax · no registration attached1 Sep+24.0%-13.2%still open
Zee BusinessZee Business · no registration attached17 Aug+5.5%-4.9%still open

Shareholding

change across 4 filings
CategorySep 26Jun 26Mar 26Dec 25Change
Promoters44.644.644.644.60.0
Foreign institutions9.710.09.29.0+0.7
Domestic institutions0.60.60.50.5+0.1
Retail & others45.244.845.745.9−0.7

As filed with the exchange for the periods ending Dec 25 to Sep 26.

Filings

latest 25 of 285
  • Credit Rating9 Oct 2026
    Medium impactCredit RatingFiling PDF ↗
  • Certificate under SEBI (Depositories and Participants) Regulations, 20187 Oct 2026
    RoutineGeneralFiling PDF ↗
  • Copy of Newspaper Publication2 Oct 2026
    RoutineGeneralFiling PDF ↗
  • Shareholders meeting1 Oct 2026
    RoutineGeneralFiling PDF ↗
  • Investor Presentation29 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Analysts/Institutional Investor Meet/Con. Call Updates25 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Trading Window23 Sept 2026
    Medium impactInsider TradingFiling PDF ↗
  • Closure of Trading Window23 Sept 2026
    Medium impactInsider TradingFiling PDF ↗
  • Intimation of Grant of Patent21 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals21 Sept 2026
    High impactLitigationFiling PDF ↗
  • Analysts/Institutional Investor Meet/Con. Call Updates7 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Intimation of Schedule of Analyst/Institutional Investor Meet under the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 20157 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Analysts/Institutional Investor Meet/Con. Call Updates7 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Analysts/Institutional Investor Meet/Con. Call Updates21 Aug 2026
    RoutineGeneralFiling PDF ↗
  • Transcript of the earnings conference call conducted on August 17, 202621 Aug 2026
    RoutineGeneralFiling PDF ↗
  • General Updates19 Aug 2026
    RoutineGeneralFiling PDF ↗
  • Analysts/Institutional Investor Meet/Con. Call Updates17 Aug 2026
    RoutineGeneralFiling PDF ↗
  • Investor Presentation17 Aug 2026
    RoutineGeneralFiling PDF ↗
  • Press Release14 Aug 2026
    RoutineGeneralFiling PDF ↗
  • Outcome of Board Meeting14 Aug 2026
    RoutineBoard MeetingFiling PDF ↗
  • Amendment to AOA/MOA13 Aug 2026
    RoutineGeneralFiling PDF ↗
  • Analysts/Institutional Investor Meet/Con. Call Updates12 Aug 2026
    RoutineGeneralFiling PDF ↗
  • General Updates7 Aug 2026
    RoutineGeneralFiling PDF ↗
  • Credit Rating7 Aug 2026
    Medium impactCredit RatingFiling PDF ↗
  • Commencement of Commercial Production31 Jul 2026
    RoutineGeneralFiling PDF ↗

The 25 most recent of 285 filings we hold for UFLEX, back to January 2024. Every filing, by day.

Disclaimer

Guidance is quoted from management commentary on quarterly earnings calls; the words are the company's own and the targets are theirs, not ours. Peer comparisons use quarterly financials sourced from Screener, with every company measured at the same fiscal quarter; the peer set is companies sharing the same industry classification, and comparisons are descriptive, not a ranking or a view. Broadcast calls are reproduced as stated on air, attributed, with the analyst's SEBI registration status where given; they are not our calls and not our view. Filings are reproduced as companies filed them to the NSE and BSE; Bharatstox does not verify, endorse or comment on their contents. This page is for informational and educational purposes only and does not constitute investment advice, research, or a recommendation to buy or sell any security. Investing in securities markets is subject to market risks. Read all related documents carefully before investing.

Bharat ke stocks, har subah.

One daily brief on what India's SEBI-registered research analysts are calling. No noise, no spam, unsubscribe whenever.